In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
Conflict of interest?
OpinionIn 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which was accepted in Australia with the same data, PharmaMar sued the EC. European Biotechnology spoke with PharmaMar’s Chairman José María Fernández Sousa-Faro.
Dutch State to sell share capital of Intravacc BV
Latest NewsThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Immunology expert joins ImmunOs Therapeutics
AppointmentsThe biopharmaceutical company ImmunOs Therapeutics AG has appointed Michael A. Curran, PhD, as Chairman of the Company´s Scientific Advisory Board.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Latest NewsTay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
Medigene licences CD40L-CD28 costimulatory switch receptor
Latest NewsGerman Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.
EU to decarbonise aviation sector through green fuel targets
Latest NewsThe European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
Latest NewsIn 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Latest NewsTargeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
Latest NewsSyngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
Latest NewsPhialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.